Targeting VEGF-VEGFR pathway by sunitinib in peripheral primitive neuroectodermal tumor, paraganglioma and epithelioid hemangioendothelioma: Three case reports

Case Reports in Oncology

Volumn 6, Issue 1, 2013, Pages 90-97

  Prochilo, Tiziana ^a   Savelli, Giordano ^b   Bertocchi, Paola ^a   Abeni, Chiara ^a   Rota, Luigina ^a   Rizzi, Anna ^a   Zaniboni, Alberto ^a  

^a UO Oncologia   (Italy)

^b Servizio di Medicina Nucleare   (Italy)

Author keywords

Antiangiogenic therapy; Epithelioid hemangioendothelioma; Paraganglioma; Peripheral primitive neuroectodermal tumor; Sunitinib

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMOZOLOMIDE; TYROSINE KINASE RECEPTOR; VASCULOTROPIN RECEPTOR; VINCRISTINE; ZOLEDRONIC ACID; CATECHOLAMINE; VASCULOTROPIN;

ABDOMINAL MASS; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE LESION; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CAPILLARY DENSITY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DYSGEUSIA; DYSURIA; EPITHELIOID HEMANGIOENDOTHELIOMA; EWING SARCOMA; FEMALE; FLANK PAIN; GASTROINTESTINAL STROMAL TUMOR; HEMANGIOENDOTHELIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; LUNG NODULE; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; OUTCOME ASSESSMENT; PANCREATIC NEUROENDOCRINE TUMOR; PARAAORTIC LYMPH NODE; PARAGANGLIOMA; PELVIS PAIN SYNDROME; PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RARE DISEASE; SCROTAL PAIN; SIDE EFFECT; SIGNAL TRANSDUCTION; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE; WEIGHT REDUCTION; ADRENALECTOMY; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE URINE LEVEL; CERVICOBRACHIAL NEURALGIA; DISEASE COURSE; DRUG MEGADOSE; DRUG TARGETING; ECHOGRAPHY; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC SCREENING; INCIDENTAL FINDING; LAMINECTOMY; NEPHROSURRENOURETERECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIC PAIN; PERICARDIAL EFFUSION; RADIATION DOSE FRACTIONATION; UROLOGIC SURGERY;

EID: 84877968961     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000348429     Document Type: Article

References (18)

1. De Bock K, Cauwenberghs S, Carmeliet P: Vessel abnormalization: another hallmark of cancer Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 2011;21:73-79.
2. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
3. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al: Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-113.
4. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
5. Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Children's Oncology Group, et al: Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:334-338.
6. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-585.
7. Dei Tos AP, Wagner AJ, Modena P, Comandone A, Leyvraz S: Epithelioid soft tissue tumors. Semin Oncol 2009;36:347-357.
8. Zhou Z, Reddy K, Guan H, Kleinerman ES: VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol Cancer Res 2007;5:1125-1132.
9. Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, et al: Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007;13:4867-4873.
10. Fuchs B, Inwards CY, Janknecht R: Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004;10:1344-1353.
11. DuBois SG, Marina N, Glade-Bender J: Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer 2010;116:749-757.
12. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al: Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005;14:2231-2239.
13. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85.
14. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, et al: Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/ pheochromocytoma. J Clin Endocrinol Metab 2009;94:5-9.
15. Stacher E, Gruber-Mösenbacher U, Halbwedl I, Dei Tos AP, Cavazza A, Papotti M, et al: The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets Lung Cancer 2009;65:49-55.
16. Emamaullee JA, Edgar R, Toso C, Thiesen A, Bain V, Bigam D, et al: Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: implications for treatment and surgical management. Liver Transpl 2010;16:191-197.
17. Park MS, Ravi V, Araujo DM: Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 2010;22:351-355.
18. Salech F, Valderrama S, Nervi B, Rodriguez JC, Oksenberg D, Koch A, et al: Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. Ann Hepatol 2011;10:99-102.